VivoSeq
Other

Total Joint Arthroplasty

21

Pipeline Programs

3

Active Trials

13

Companies Involved

Total Joint Arthroplasty is an emerging landscape with 21 programs across 13 companies. The most active players are Viatris Specialty LLC, Neurim Pharmaceuticals Ltd., Hikma Pharmaceuticals LLC. 6 therapies are approved with 3 more in late-stage development.

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

63/100

Attrition Rate

29/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

24

clinical trials

Completed12 · 50%
Withdrawn6 · 25%
Unknown status2 · 8%
Recruiting1 · 4%
Active, not recruiting1 · 4%
Not yet recruiting1 · 4%
Other1 · 4%

Trial Activity

24 trials

Total Joint Arthroplasty and Sleep
Completed··Phase 4·NCT03968939·55 enrolled
Melatonin Use After Primary Total Joint Arthroplasty
Completed·NNYU Langone Health·Phase 1·NCT04795336·294 enrolled
Tranexamic Acid Dosing for Total Joint Arthroplasty
Completed··Phase 4·NCT02584725·84 enrolled
Intraoperative Ketamine for Patients Undergoing Total Joint Arthroplasty
Completed··Phase 1·NCT04437888·200 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)